KRTL Biotech (KRTL Holding) Acquires Majority Interest in Sigma Corp (Bolivia)
September 2, 2025
KRTL Biotech, a wholly owned subsidiary of KRTL Holding Group, Inc., completed a merger-by-exchange to acquire 99% of Industria Químico Farmacéutica Sigma Corp. S.R.L. (SIGMA), a Bolivian pharmaceutical manufacturer. The Wilstermann Family received 490,000,000 KRTL Biotech common shares (49% of KRTL Biotech) and Patricia Wilstermann received a preferred share and a permanent board seat; SIGMA will be consolidated into KRTL Biotech's financials under U.S. GAAP.
- Buyers
- KRTL Biotech, Inc., KRTL Holding Group, Inc.
- Targets
- Industria Químico Farmacéutica Sigma Corp. S.R.L.
- Sellers
- Wilstermann Family
- Industry
- Pharmaceuticals
- Location
- Cochabamba, Bolivia
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
KELIX bio to Acquire Pharmaceutical Institute (PHI) in Rabat, Morocco
March 8, 2022
Pharmaceuticals
KELIX bio, a pan-African biopharmaceutical platform, entered into a binding commitment to acquire Pharmaceutical Institute (PHI), a leading pharmaceutical manufacturer in Rabat, Morocco. The deal marks KELIX bio’s first entry into Morocco and is intended to strengthen the company’s manufacturing and distribution presence as Morocco expands universal health coverage.
-
KRTL Holding Group Acquires Neurogen Brain Balancing, LLC
April 9, 2025
Healthcare Services
KRTL Holding Group Inc. has acquired 100% of Neurogen Brain Balancing, LLC, a California-based neurotechnology company that provides non-invasive brain balancing therapies and personalized cognitive optimization systems. The stock-based transaction includes a profit-sharing agreement and KRTL will support Neurogen's regulatory pathway and international expansion, including FDA-related services and integration into KRTL's operational infrastructure.
-
Pharmaron Acquires 82.54% of Biortus Biosciences
October 28, 2025
Healthcare Services
Pharmaron Beijing Co., Limited has entered into a definitive Share Purchase Agreement to acquire 82.54% of Biortus Biosciences Co., Ltd. and its affiliates. The transaction is expected to close after satisfaction of customary closing conditions and is intended to strengthen Pharmaron’s structure-based drug discovery and protein science capabilities.
-
QIAGEN Acquires 96% Stake in BLIRT S.A.
May 11, 2022
Biotechnology
QIAGEN N.V. has acquired a more than 96% majority ownership stake in BLIRT S.A., a Gdansk, Poland–based manufacturer of recombinant enzymes and molecular biology reagents. The deal (expected to close in Q2 2022) adds R&D and industrial-scale manufacturing capacity, expands QIAGEN's sample technologies business and broadens its geographic and commercial reach while strengthening supply-chain resilience.
-
Molecular Designs Acquires Lamda Biotech
September 25, 2024
Biotechnology
Molecular Designs, a Birmingham-based provider of PCR assays and related reagents and equipment, has acquired Lamda Biotech, a St. Louis provider of molecular biology research products and kits. The deal will expand Molecular Designs’ product portfolio and manufacturing capacity while broadening access to academic research and pharmaceutical customers and strengthening R&D and technical talent.
-
Medix Biochemica Group Acquires Bioresource Technology (BRT)
June 21, 2022
Biotechnology
Medix Biochemica has acquired a 100% stake in US-based Bioresource Technology (BRT) to expand its base matrix capabilities and strengthen its presence in the United States. BRT will be integrated into Medix Biochemica’s IVD Biomaterials Business Unit (St. Louis) while operations continue in Weston, Florida, and BRT leadership will serve as strategic advisors.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.